Etoposide in Treating Young Patients With Relapsed Ependymoma

NCT00278252 | Unknown Phase 2

• 3 other identifiers: CCLG-CNS-2001-4CDR0000454543EU-20576
• Study Type: interventional
• Target: 14
• Locations: 1 country
• Sites: 1

Brief Summary

RATIONALE: Drugs used in chemotherapy, such as etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well etoposide works in treating young patients with ependymoma.

Conditions

Brain and Central Nervous System Tumors

Keywords

recurrent childhood ependymoma; childhood infratentorial ependymoma; childhood supratentorial ependymoma

Outcome Measures

Primary Outcomes (1)

• Response rate by MRI after course 3

Secondary Outcomes (1)

• Second surgery or additional radiotherapy in responding patients as assessed by MRI scan after course 3 or 6

Interventions

etoposide DRUG

conventional surgery PROCEDURE

Eligibility Criteria

• Age: Up to 21 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

DISEASE CHARACTERISTICS: * Histologically confirmed intracranial ependymoma at first, second, or third relapse * Anaplastic (malignant) or low-grade ependymoma (cellular, papillary, clear cell, or mixed variants) * Unequivocal evidence of tumor recurrence or progression by MRI scan after failing conventional treatment (e.g., primary surgery and adjuvant radiotherapy) for initial or recurrent disease * Unresectable disease OR not amenable to complete surgical resection * Measurable enhancing or non-enhancing disease on baseline scan performed within the past 2 weeks * Patients who have undergone prior surgery must have residual measurable disease PATIENT CHARACTERISTICS: * Lansky performance status 30-100% * Life expectancy ≥ 8 weeks * Absolute neutrophil count \> 1,000/mm\^3 * Platelet count \> 100,000/mm\^3 * Serum total bilirubin normal * AST \< 2 times upper limit of normal * No unrelated medical condition (e.g., renal or liver impairment) that would preclude chemotherapy treatment * No active infection * No known HIV positivity PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No radiotherapy within the past 6 weeks * No chemotherapy within the past 4 weeks * Prior IV etoposide allowed

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• Children's Cancer and Leukaemia Group: lead

Study Sites (1)

Leeds Cancer Centre at St. James's University Hospital

Leeds, England, LS9 7TF, United Kingdom

RECRUITING

Related Publications (1)

• Apps JR, Maycock S, Ellison DW, Jaspan T, Ritzmann TA, Macarthur D, Mallucci C, Wheatley K, Veal GJ, Grundy RG, Picton S. Phase II study of intravenous etoposide in patients with relapsed ependymoma (CNS 2001 04). Neurooncol Adv. 2022 Apr 13;4(1):vdac053. doi: 10.1093/noajnl/vdac053. eCollection 2022 Jan-Dec.

  PMID: 35591977 DERIVED

MeSH Terms

Conditions

Central Nervous System Neoplasms; Familial ependymoma

Interventions

Etoposide

Condition Hierarchy (Ancestors)

Nervous System Neoplasms; Neoplasms by Site; Neoplasms; Nervous System Diseases

Intervention Hierarchy (Ancestors)

Podophyllotoxin; Tetrahydronaphthalenes; Naphthalenes; Polycyclic Aromatic Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Polycyclic Compounds; Glucosides; Glycosides; Carbohydrates

Study Officials

• Linda S. Lashford

  The Christie NHS Foundation Trust

• Susan V. Picton, MD

  Leeds Cancer Centre at St. James's University Hospital

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: phase 2
• Masking: NONE
• Purpose: TREATMENT
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: January 16, 2006
• First Posted: January 18, 2006
• Study Start: July 1, 2001
• Primary Completion: July 1, 2010
• Last Updated: August 7, 2013

Record last verified: 2009-06

Locations

GB (1)